<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-125348</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Analysis of the causes leading to withdrawal of the treatment with triple antivial therapy for hepatitis C patients</dc:title>
<dc:description xml:lang="en">Objective: To assess causes of suspension of hepatitis C treatment in patients receiving triple antiviral therapy (peginterferon+ ribavirin + protease inhibitor).Methods: Retrospective observational study of patients who recived triple antiretroviral therapy agaisnst hepatitis C between January 2012 - March 2013 and discontinued their treatment. Results: Of 156 patients who initiated therapy, 41 discontinued treatment: Nineteen due to adverse events, being dermatological events in seven patients ( 36.8 %), intolerance in six(31.6%) and hematologic toxicity in four (15.8%) . Sixteen patients discontinued treatment for beeing ineffectiveness. Patients with higher inefficacy failure rate were &#147;null-responders&#148; (32.3% ) while the group of &#147;relapsers&#148; were the one with the highest rate of toxicity suspensions (15.6%). Two patients died during treatment for pneumonia. Conclusions: Triple therapy with boceprevir and telaprevir is associated with a significant number of treatment failures due to toxicity and ineffectiveness (AU)</dc:description>
<dc:creator>Ruiz Ramos, J</dc:creator>
<dc:creator>Lorente Fernández, L</dc:creator>
<dc:creator>Gil Gómez, I</dc:creator>
<dc:creator>Poveda Andrés, J. L</dc:creator>
<dc:creator>Cueto Sola, M</dc:creator>
<dc:creator>Monte Boquet, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Evaluar las causas de suspensión de tratamient of rente a Hepatitis C que reciben triple terapia antiviral (pegin-terferon + ribavirina + inhibidor de proteasa).Métodos: Estudio observacional retrospectivo de pacientes que iniciaron triple terapia antiviral entre enero 2012 - marzo 2013y suspendieron el tratamiento antes de completar el mismo. Resultados: De 156 pacientes que iniciaron triple terapia, 41interrumpieron el tratamiento: Diecinueve por toxicidad, siendo dermatológica en siete pacientes (36,8%), intolerancia en seis(31,6%) y hematológica en cuatro (15,8%). Dieciséis pacientes suspendieron todo el tratamiento por ineficacia. El grupo de pacientes con mayor porcentaje de fracasos por ineficacia fueron los &#147;no respondedores&#148; (32,3%) mientras que el grupo de pacientes &#147;recidivantes&#148; fueron el grupo con mayor porcentaje de suspensiones por toxicidad (15,6%). Dos (..) (AU)</dc:description>
<dc:source>Farm Hosp;38(3): 223-226, mayo-jun. 2014. tab</dc:source>
<dc:identifier>ibc-125348</dc:identifier>
<dc:title xml:lang="es">Análisis de las causas de suspensión de tratamiento con triple terapia antivrial en pacientes con hepatitis C</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d^s22054</dc:subject>
<dc:subject>^d33344^s22057</dc:subject>
<dc:subject>^d36291</dc:subject>
<dc:subject>^d30033^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12663^s22000</dc:subject>
<dc:subject>^d1002^s22000</dc:subject>
<dc:subject>^d11924^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>201406</dc:date>
</metadata>
</record>
</ibecs-document>
